Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months

Steven D Vold, Lilit Voskanyan, Manfred Tetz, Gerd Auffarth, Imran Masood, Leon Au, Iqbal Ike K Ahmed, Hady Saheb, Steven D Vold, Lilit Voskanyan, Manfred Tetz, Gerd Auffarth, Imran Masood, Leon Au, Iqbal Ike K Ahmed, Hady Saheb

Abstract

Purpose: To examine outcomes through 36 months in phakic eyes with newly diagnosed primary open-angle glaucoma (POAG) naïve to therapy randomized to treatment with two trabecular micro-bypass stents or topical prostaglandin.

Methods: Subjects with POAG naïve to therapy, with intraocular pressure (IOP) ≥21 and ≤40 mmHg, were randomized to implantation of two stents or travoprost. Additional medication was to be prescribed post-treatment for elevated IOP or glaucomatous optic nerve findings. Of 101 randomized subjects, 100 subjects were followed for 24 months and 73 subjects were followed for 36 months. Follow-up on all subjects is ongoing.

Results: In this randomized cohort of 101 POAG subjects, 54 subjects underwent 2-stent surgery and 47 received topical travoprost. Mean pre-treatment IOP was 25.5 ± 2.5 mmHg in stent-treated eyes and 25.1 ± 4.6 mmHg in medication-treated eyes. By 3 years, mean IOP was 14.6 mmHg in stent eyes (with medication added in 6 eyes) and 15.3 mmHg in travoprost eyes (with a second medication added in 11 eyes). In the subset of eyes that did not require additional medical therapy, mean IOP was 14.5 mmHg and 15.7 mmHg in the respective groups. Ninety-one percent of stent eyes had 3-year IOP ≤18 mmHg without additional therapy (62% ≤ 15 mmHg) and 79% of travoprost eyes had 3-year IOP ≤18 mmHg (21% ≤ 15 mmHg). Safety was favorable in both groups.

Conclusions: In this prospective, randomized comparison of subjects with newly diagnosed POAG naïve to therapy, substantial IOP reduction with a favorable low complication rate was shown through 3 years after either 2 trabecular stents implanted as the sole procedure or topical travoprost therapy. These data suggest 2-stent implantation may be a viable initial treatment option comparable to topical prostaglandin in newly diagnosed POAG patients.

Trial registration: ClinicalTrials.gov identifier, NCT01443988.

Funding: Glaukos Corporation, Laguna Hills, CA.

Keywords: Glaucoma; IOP; MIGS; POAG; Prostaglandin; Trabecular bypass.

Figures

Fig. 1
Fig. 1
Mean IOP (mmHg) and number of subjects through 3 years, available eyes of randomized cohort*. IOP intraocular pressure
Fig. 2
Fig. 2
Mean IOP (mmHG) and number of subjects through 3 years in Eyes without additional medical therapy, available eyes of randomized cohort*. IOP intraocular pressure
Fig. 3
Fig. 3
Proportional analysis of post-treatment IOP, percent ≤15, ≤18 mmHg without additional therapy, available eyes of randomized cohort*. IOP intraocular pressure
Fig. 4
Fig. 4
Proportional analysis of BCVA through 3 years, available eyes of randomized cohort*. BCVA best-corrected visual acuity, PRE preoperative

References

    1. Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116(11 Suppl):S30–S36. doi: 10.1016/j.ophtha.2009.06.024.
    1. Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122:1308–1316. doi: 10.1016/j.ophtha.2015.03.026.
    1. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol. 2004;137:3–12. doi: 10.1016/j.ajo.2003.10.035.
    1. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598–606. doi: 10.1016/j.ajo.2005.04.051.
    1. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS) Invest Ophthalmol Vis Sci. 2007;48:5052–5057. doi: 10.1167/iovs.07-0290.
    1. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open angle glaucoma suspects. Am J Ophthalmol. 2004;137:S13–S16. doi: 10.1016/j.ajo.2003.10.034.
    1. Mansberger SL. Are you compliant with addressing glaucoma adherence? Am J Ophthalmol. 2010;149(1):1. doi: 10.1016/j.ajo.2009.08.011.
    1. Nagar M, Ogunyomade A, O’Brart DP, et al. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2005;89:1413–1417. doi: 10.1136/bjo.2004.052795.
    1. Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012;23:96–104. doi: 10.1097/ICU.0b013e32834ff1e7.
    1. Regulatory Affairs Division, Glaukos Corporation, Laguna Hills, CA, USA. Data on file.
    1. Fea AM. Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma. J Cataract Refract Surg. 2010;36:407–412. doi: 10.1016/j.jcrs.2009.10.031.
    1. Samuelson TW, Katz LJ, Wells JM, Duh Y-J, Giamporcaro JE. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118:459–467. doi: 10.1016/j.ophtha.2010.07.007.
    1. Craven ER, Katz LJ, Wells JM, Giamporcaro JE. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. J Cataract Refract Surg. 2012;38:1339–1345. doi: 10.1016/j.jcrs.2012.03.025.
    1. Arriola-Villalobos P, Martinez-de-la-Casa J, Diaz-Valle D, et al. Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study. Br J Ophthalmol. 2012;96:645–649. doi: 10.1136/bjophthalmol-2011-300218.
    1. Neuhann TH. Trabecular micro-bypass stent implantation during small-incision cataract surgery for open-angle glaucoma ocular hypertension: long-term results. J Cataract Refract Surg. 2015;41:2664–2671. doi: 10.1016/j.jcrs.2015.06.032.
    1. Fea AM, Consolandi G, Zola M, et al. Micro-bypass implantation for primary open-angle glaucoma combined with phacoemulsification: 4-year follow-up. J Ophthalmol. 2015. Article ID 795357. 10.1155/2015/795357. Accessed July 12, 2016.
    1. Spiegel D, Wetzel W, Neuhann T, et al. Coexistent primary open-angle glaucoma and cataract: interim analysis of a trabecular micro-bypass stent and concurrent cataract surgery. Eur J Ophthalmol. 2009;19:393–399.
    1. Belovay GW, Naqi A, Chan BJ, Rateb M, Ahmed II. Using multiple trabecular micro-bypass stents in cataract patients to treat open-angle glaucoma. J Cataract Refract Surg. 2012;38(11):1911–1917. doi: 10.1016/j.jcrs.2012.07.017.
    1. Ahmed II, Katz LJ, Chang DF, et al. Prospective evaluation of microinvasive glaucoma surgery with trabecular microbypass stents and prostaglandin in open-angle glaucoma. J Cataract Refract Surg. 2014;40:1295–1300. doi: 10.1016/j.jcrs.2014.07.004.
    1. Donnenfeld ED, Solomon KD, Voskanyan L, et al. A prospective 3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma. Clin Ophthalmol. 2015;9:2057–2065.
    1. Katz LJ, Erb C, Carceller Guillamet AC, et al. Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication. Clin Ophthalmol. 2015;9:2313–2320.
    1. Rulli E, Biagioli E, Riva I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures. A systematic review and meta-analysis. JAMA Ophthalmol. 2013;131:1573–1582. doi: 10.1001/jamaophthalmol.2013.5059.
    1. Höh H, Grisanti S, Grisanti S, Rau M, Ianchulev S. Two-year clinical experience with the CyPass micro-stent: safety and surgical outcomes of a novel supraciliary micro-stent. Klin Monbl Augenheilkd. 2014;231(4):377–381. doi: 10.1055/s-0034-1368214.
    1. Sarkisian S. Combined cataract surgery and supraciliary microstent implantation for open-angle glaucoma: multicenter 3-year results. Presented at 2016 American Society of Cataract and Refractive Surgeons, May, 2016, New Orleans, LA, USA.
    1. Vold S. Prospective, randomized evaluation of microinvasive glaucoma surgery (MIGS) with two trabecular microbypass stents vs. prostaglandin in open-angle or pseudoexfoliative glaucoma or ocular hypertension naïve to therapy. Poster presented at 2015 Annual Meeting of the American Glaucoma Society, February 26—March 1, 2015, Coronado, CA.
    1. . Accessed July 20, 2016.
    1. Terminology and guidelines for glaucoma. ISBN 978-88-98320-05-09. Copyright 2014 European Glaucoma Society. . Accessed July 22, 2016.
    1. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically. The Travatan dosing aid study. Ophthalmology. 2009;116:191–199. doi: 10.1016/j.ophtha.2008.09.004.
    1. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533–540. doi: 10.1016/j.ajo.2007.06.012.
    1. Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116:S30–S36. doi: 10.1016/j.ophtha.2009.06.024.
    1. Red Book ™. Ann Arbor: Truven Health Analytics; 2013. . Accessed July 6, 2016.
    1. Salim S, Shields MB. Glaucoma and systemic diseases. Surv Ophthalmol. 2010;55:64–77. doi: 10.1016/j.survophthal.2009.03.006.
    1. Peace J, Ahlberg P, Wagner M, et al. Equivalent IOP lowering found when travoprost is preserved with polyquaternium or benzalkonium chloride. Am J Ophthalmol. 2015;160:266–274. doi: 10.1016/j.ajo.2015.04.041.
    1. Parrish RK, Palmberg P, Sheu W-P, XLT Study Group A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688–703. doi: 10.1016/S0002-9394(03)00098-9.
    1. Lanzl I, Hamacher T, Rosbach K, et al. Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension. Clin Ophthalmol. 2013;7:901–910.
    1. Brown RH, Gibson Z, Zhong L, Lynch MG. Intraocular pressure reduction after cataract surgery with implantation of a trabecular microbypass device. J Cataract Refract Surg. 2015;41(6):1318–1319. doi: 10.1016/j.jcrs.2015.01.015.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren